Get the Stockscreener App
1.50
2.04%
0.03
Alector Inc stock is traded at $1.50, with a volume of 500.12K.
It is up +2.04% in the last 24 hours and down -3.85% over the past month.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
See More
Previous Close:
$1.47
Open:
$1.43
24h Volume:
500.12K
Relative Volume:
0.70
Market Cap:
$166.54M
Revenue:
$21.05M
Net Income/Loss:
$-142.93M
P/E Ratio:
-1.0795
EPS:
-1.3895
Net Cash Flow:
$-184.07M
1W Performance:
-6.83%
1M Performance:
-3.85%
6M Performance:
-18.48%
1Y Performance:
-10.18%
1-Day Range:
$1.42
$1.5189
1-Week Range:
$1.37
$1.61
52-Week Range:
$1.09
$3.3999
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.50 | 163.21M | 21.05M | -142.93M | -184.07M | -1.3895 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-10-26 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-22-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-22-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-22-25 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary - Quartr
Alector (ALEC) Proxy filing Summary - Quartr
Alector Q1 2026 Earnings: Narrower Loss Surprises, Yet Shares Dip Amid Revenue AbsenceCapex Guidance - DonanımHaber
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
GSK exits Alector neurodegeneration alliance after trial failures - The Pharma Letter
Form 4 Alector Inc For: 9 July By Investing.com - Investing.com Nigeria
Alector (ALEC) awards 20,000 RSUs to principal accounting officer - Stock Titan
GSK ends brain drug alliance with Alector - BioPharma Dive
GSK Bids Farewell To Alector Dementia Deal - insights.citeline.com
GSK Walks Away From AlectorPipeline Reset Story Begins (NASDAQ:ALEC) - Seeking Alpha
GSK Terminates Neuroscience Collaboration with Alector Following Drug Trial SetbacksEPS Surprise History - dars.gov.et
Alector stock plummets 13% as GSK terminates neuroscience pact (GSK:NYSE) - Seeking Alpha
Alector (ALEC) Shares Drop 13% Following Termination of GSK Coll - GuruFocus
Alector and GSK partnership to end after dementia, Alzheimer’s drug failures - whbl.com
Alector, Inc. Terminates Material Definitive Agreement – Key 8-K Filing Update July 2026 - Minichart
Alector and GSK partnership to end after dementia, Alzheimer's drug failures - Reuters
Alector Ends GSK Collaboration, Retires Hercules Capital Debt - TipRanks
Alector to End GSK Progranulin Collaboration; Repays $10.4 Million Hercules Loan - TradingView
Alector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loan - Stock Titan
According to a filing submitted to the U.S. Securities and Exchange Commission (SEC), GlaxoSmithKline has decided to terminate its collaboration and licensing agreement with Alector Inc., with the termination to take effect on January 2, 2027. - Bitget
ALEC Q1 2026 Earnings: Narrowing Losses with 39.95% EPS Beat; Stock Rises 2.49%Investor Earnings Call - dars.gov.et
Alector Inc. (ALEC) Recovers From Support as Shares Edge HigherValue Area Low - DonanımHaber
ALEC Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive SentimentCEO Earnings Statement - dars.gov.et
0Z2 Forecast — Price Target — Prediction for 2027 - TradingView
Alector, Inc. Actuals & Estimates (NASDAQ:ALEC) - TradingView
ALEC Forecast — Price Target — Prediction for 2027 - TradingView
Alector (ALEC) Surges 11.45% as Shares Test Key Resistance at $2.1Buy Signal Reports - dars.gov.et
A2PCBM Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Alector, Inc. – GETTEX:0Z2 - TradingView
Price to sales forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Enterprise value to revenue forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Price to sales forward of Alector, Inc. – GETTEX:0Z2 - TradingView
Price to book forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Enterprise value to EBITDA forward of Alector, Inc. – GETTEX:0Z2 - TradingView
Enterprise value to EBIT forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Alector Inc. (ALEC) Q1 2026 Earnings: EPS Beat on Narrower Loss, No Revenue YetEarnings Season Outlook - dars.gov.et
Alector Inc. (ALEC) Edges Higher as Stock Approaches Key ResistanceHead and Shoulders - dars.gov.et
ALEC Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit RallyGeographic Revenue Trends - dars.gov.et
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough - Yahoo Finance
Alector Inc (ALEC) Institutional Confidence - TradingKey
Alector Inc (ALEC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alector Inc (ALEC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alector Inc (ALEC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alector Inc (ALEC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alector Shareholders Back Directors, Auditor and Executive Pay - TipRanks
[8-K] Alector, Inc. Reports Material Event - Stock Titan
Alector (ALEC) director Kristine Yaffe granted 28,700 RSUs and options - Stock Titan
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):